Kostas Athanasakis 1 . Show Affiliations »
Abstract
BACKGROUND: Hypertension (HT), albeit a modifiable risk factor of cardiovascular morbidity and mortality, remains one of the main contributors to the total disease burden internationally and, thus, inevitably one of the basic cost drivers in healthcare systems. CONCLUSION: Taking the above into account, this brief narrative review aims at presenting the main findings of the international health economics literature on HT with regards to four key areas: a) the costs attributable to HT, b) the effects of HT on patient well-being, c) the cost-effectiveness of pharmaceutical interventions against high blood pressure, and, d) the costs and benefits of preventive measures against HT. Bearing in mind the available evidence on disease costs and the efficiency of interventions, HT must constitute a primary objective of modern health policy, internationally. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Hypertension (HT), albeit a modifiable risk factor of cardiovascular morbidity and mortality, remains one of the main contributors to the total disease burden internationally and, thus, inevitably one of the basic cost drivers in healthcare systems. CONCLUSION: Taking the above into account, this brief narrative review aims at presenting the main findings of the international health economics literature on HT with regards to four key areas: a) the costs attributable to HT, b) the effects of HT on patient well-being, c) the cost-effectiveness of pharmaceutical interventions against high blood pressure, and, d) the costs and benefits of preventive measures against HT. Bearing in mind the available evidence on disease costs and the efficiency of interventions, HT must constitute a primary objective of modern health policy, internationally. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Disease
Species
Keywords:
Hypertension; cost; cost-effectiveness; health economics; health-related quality of life
Mesh: See more »
Substances: See more »
Year: 2017
PMID: 28412912 DOI: 10.2174/1570161115666170413145125
Source DB: PubMed Journal: Curr Vasc Pharmacol ISSN: 1570-1611 Impact factor: 2.719